IP Library Granted Patent US 8,912,199
Granted Patent B2
US 8,912,199 · App. 14/058,839 · Granted Dec 16, 2014

Modulators of ATP-binding cassette transporters

Inventors: Sara S. Hadida Ruah (La Jolla, CA); Peter D. J. Grootenhuis (San Diego, CA); Fredrick Van Goor (San Diego, CA); Jinglan Zhou (San Diego, CA); Brian Bear (Oceanside, CA); Mark T. Miller (San Diego, CA); Jason McCartney (Cardiff by the Sea, CA); Mehdi Michel Jamel Numa (San Diego, CA); Xiaoqing Yang (San Diego, CA)
Assignee: Vertex Pharmaceuticals Incorporated
G01N33/5008C07D471/04C07D405/14C07D405/12C07D403/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,912,199
App. No.
14/058,839
Granted
Dec 16, 2014
Kind
B2
Abstract

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Claims (53)

1. A method of treating or lessening the severity of pancreatic insufficiency or male infertility in a patient, comprising the step of administering to said patient an effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof, wherein

R 1 is —Z A R 4 , wherein each Z A is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z A are optionally and independently replaced by —CO—, —CS—, —CONR A —, —CONR A NR A —, —CO 2 —, —OCO—, —NR A CO 2 —, —O—, —NR A CONR A —, —OCONR A —, —NR A NR A —, —NR A CO—, —S—, —SO—, —SO 2 —, —NR A —, —SO 2 NR A —, —NR A SO 2 —, or —NR A SO 2 NR A —,

Each R 4 is independently R A , halo, —OH, —NH 2 , —NO 2 , —CN, or —OCF 3 ,

Each R A is independently hydrogen, an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl;

Each R 2 is independently —Z B R 5 , wherein each Z B is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z B are optionally and independently replaced by —CO—, —CS—, —CONR B —, —CONR B NR B —, —CO 2 —, —OCO—, —NR B CO 2 —, —O—, —NR B CONR B —, —OCONR B —, —NR B NR B —, —NR B CO—, —S—, —SO—, —SO 2 —, —NR B —, —SO 2 NR B —, —NR B SO 2 —, or —NR B SO 2 NR B —,

Each R 5 is independently R B , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 ,

Each R B is independently hydrogen, an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl,

Or, any two adjacent R 2 groups together with the atoms to which they are attached form an optionally substituted carbocycle or an optionally substituted heterocycle;

Ring A is an optionally substituted 3-7 membered monocyclic ring having 0-3 heteroatoms selected from N, O, and S;

Ring B is a group having formula Ia:

or a pharmaceutically acceptable salt thereof, wherein

p is 0-2,

Each R 3 and R′ 3 is independently —Z C R 6 , where each Z C is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z C are optionally and independently replaced by —CO—, —CS—, —CONR C —, —CONR C NR C —, —CO 2 —, —OCO—, —NR C CO 2 —, —O—, —NR C CONR C —, —OCONR C —, —NR C NR C —, —NR C CO—, —S—, —SO—, —SO 2 —, —NR C —, —SO 2 NR C —, —NR C SO 2 —, or —NR C SO 2 NR C —,

Each R 6 is independently R C , halo, —OH, —NH 2 , —NO 2 , —CN, or —OCF 3 ,

Each R C is independently hydrogen, an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl,

Or, any two adjacent R 3 groups together with the atoms to which they are attached form an optionally substituted heterocycle; and

n is 1-3.

2. The method of claim 1 , wherein:

R 1 is —Z A R 4 , wherein each Z A is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z A are optionally and independently replaced by —CO—, —CS—, —CONR A —, —CONR A NR A —, —CO 2 —, —OCO—, —NR A CO 2 —, —O—, —NR A CONR A —, —OCONR A —, —NR A NR A —, —NR A CO—, —S—, —SO—, —SO 2 —, —NR A —, —SO 2 NR A —, —NR A SO 2 —, or —NR A SO 2 NR A —;

Each R 4 is independently R A , halo, —OH, —NH 2 , —NO 2 , —CN, or —OCF 3 ;

Each R A is independently hydrogen, an optionally substituted aliphatic, an optionally substituted cycloaliphatic, or an optionally substituted aryl;

n is 2 and the two R 2 are adjacent to each other and together with the atoms to which they are attached form

Ring A is an optionally substituted 3-7 membered monocyclic ring;

Ring B is a group of the formula

or a pharmaceutically acceptable salt thereof, wherein

p is 0-2;

Each R 3 and R′ 3 is independently —Z C R 6 , where each Z C is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z C are optionally and independently replaced by —CO—, —CS—, —CONR C —, —CONR C NR C —, —CO 2 —, —OCO—, —NR C CO 2 —, —O—, —NR C CONR C —, —OCONR C —, —NR C NR C —, —NR C CO—, —S—, —SO—, —SO 2 —, —NR C —, —SO 2 NR C —, —NR C SO 2 —, or —NR C SO 2 NR C —;

Each R 6 is independently R C , halo, —OH, —NH 2 , —NO 2 , —CN, or —OCF 3 ; and

Each R C is independently hydrogen, an optionally substituted aliphatic, an optionally substituted cycloaliphatic, or an optionally substituted aryl;

Or, any two adjacent R 3 groups together with the atoms to which they are attached form an optionally substituted heterocycle.

3. The method of claim 2 , wherein R 1 is —Z A R 4 , Z A is a bond, and R 4 is hydrogen.

4. The method of claim 2 , wherein ring A is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, each of which is optionally substituted with 1-3 of halo, hydroxy, C 1-5 aliphatic, or combinations thereof.

5. The method of claim 2 , wherein ring A is an optionally substituted 3-7 membered monocyclic heterocycloaliphatic.

6. The method of claim 2 wherein ring A is one selected from

wherein

Each R 9 is independently —Z E R 10 , wherein each Z E is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z E are optionally and independently replaced by —CO—, —CS—, —CONR E —, —CO 2 —, —OCO—, —NR E CO 2 —, —O—, —NR E CONR E —, —OCONR E —, —NR E NR E —, —NR E CO—, —S—, —SO—, —SO 2 —, —NR E —, —SO 2 NR E —, —NR E SO 2 —, or —NR E SO 2 NR E —;

Each R 10 is independently R E , —OH, —NH 2 , —NO 2 , —CN, —CF 3 , oxo, or —OCF 3 ,

Each R E is independently hydrogen, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl; and

q is 0-5.

7. The method of claim 2 , wherein R′ 3 is H.

8. The method of claim 2 , wherein one of R 3 or R′ 3 is an optionally substituted acyl group.

9. The method of claim 2 , wherein one of R 3 or R′ 3 is an (alkoxy)carbonyl optionally substituted with 1-3 of halo, hydroxy, or combinations thereof.

10. The method of claim 2 , wherein one of R 3 or R′ 3 is an (aliphatic)carbonyl optionally substituted with 1-3 of halo, hydroxy, or combinations thereof.

11. The method of claim 2 , wherein one of R 3 or R′ 3 is a (cycloaliphatic)carbonyl or a (heterocycloaliphatic)carbonyl, each is optionally substituted with 1-3 of aliphatic, halo, hydroxy, nitro, cyano, or combinations thereof.

12. The method of claim 11 , wherein one of R 3 or R′ 3 is (piperidine-1-yl)carbonyl, (pyrrolidine-1-yl)carbonyl, (morpholine-4-yl)carbonyl, (piperazine-1-yl)carbonyl, (cyclopropyl)carbonyl, (cyclobutyl)carbonyl, (cyclopentyl)carbonyl, (cyclohexyl)carbonyl, or (cycloheptyl)carbonyl, each of which is each of which is optionally substituted with 1-3 of halo, hydroxy, cyano, nitro, aliphatic, or combinations thereof.

13. The method of claim 2 , wherein R 3 is optionally substituted (aliphatic)amido that is attached to the 2 or 3 position on the indole ring of formula Ia.

14. The method of claim 13 , wherein R 3 is (N,N-dimethyl(amino))carbonyl, (methyl(amino))carbonyl, (ethyl(amino))carbonyl, (propyl(amino))carbonyl, (prop-2-yl(amino))carbonyl, (dimethyl(but-2-yl(amino)))carbonyl, (tertbutyl(amino))carbonyl, (butyl(amino))carbonyl, each of which is optionally substituted with 1-3 of halo, hydroxy, cycloaliphatic, heterocycloaliphatic, aryl, heteroaryl, or combinations thereof.

15. The method of claim 2 , wherein R′ 3 is

wherein R 31 is H or a C 1-2 aliphatic that is optionally substituted with 1-3 of halo, —OH, or combinations thereof, R 32 is -L-R 33 , wherein L is a bond, —CH 2 —, —CH 2 O—, —CH 2 NHS(O) 2 —, —CH 2 C(O)—, —CH 2 NHC(O)—, or —CH 2 NH—, and R 33 is hydrogen, or C 1-2 aliphatic, cycloaliphatic, heterocycloaliphatic, or heteroaryl, each of which is optionally substituted with 1 of —OH, —NH 2 , or —CN.

16. The method of claim 2 , wherein R′ 3 is independently selected from one of the following: —H, —CH 3 , —CH 2 CH 3 , —C(O)CH 3 , —CH 2 CH 2 OH, —C(O)OCH 3 ,

17. The method of claim 1 , wherein the compound is:

.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
ASSIGNEE CHANGE OF ADDRESS Recorded Feb 11, 2016
From: VERTEX PHARMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 037781/0332 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2013
From: YANG, XIAOQING; HADIDA RUAH, SARA S; GROOTENHUIS, PETER D.J.; VAN GOOR, FREDRICK; ZHOU, JINGLAN; BEAR, BRIAN; MILLER, MARK T.; MCCARTNEY, JASON; NUMA, MEHDI MICHEL JAMEL
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 031651/0698 →
Continuity (4)
Continuation 12829879 · Jul 2, 2010
Division 11786001 · Apr 9, 2007
Provisional Application 60790459 · Apr 7, 2006
Related Publication 20140057906A1 · Feb 27, 2014